Alpha DNA Investment Management LLC Buys Shares of 3,596 Cencora, Inc. (NYSE:COR)

Alpha DNA Investment Management LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,596 shares of the company's stock, valued at approximately $808,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. First Commonwealth Financial Corp PA lifted its position in Cencora by 4.1% in the fourth quarter. First Commonwealth Financial Corp PA now owns 3,755 shares of the company's stock valued at $844,000 after purchasing an additional 149 shares during the last quarter. Farringdon Capital Ltd. bought a new stake in Cencora during the 4th quarter valued at $322,000. Zacks Investment Management purchased a new stake in Cencora during the 4th quarter valued at $386,000. NewEdge Advisors LLC increased its position in shares of Cencora by 2.5% in the fourth quarter. NewEdge Advisors LLC now owns 227,423 shares of the company's stock valued at $51,097,000 after acquiring an additional 5,590 shares during the period. Finally, Gabelli Funds LLC raised its stake in shares of Cencora by 1.3% during the fourth quarter. Gabelli Funds LLC now owns 56,725 shares of the company's stock valued at $12,745,000 after acquiring an additional 725 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Down 1.5 %

NYSE COR traded down $4.35 during trading hours on Wednesday, reaching $281.92. 947,243 shares of the company's stock traded hands, compared to its average volume of 1,508,807. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $296.65. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a 50-day simple moving average of $265.58 and a 200 day simple moving average of $248.02. The firm has a market cap of $54.67 billion, a PE ratio of 40.10, a PEG ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.78%. Cencora's payout ratio is presently 31.29%.

Analysts Set New Price Targets

COR has been the topic of several recent analyst reports. Morgan Stanley set a $288.00 target price on Cencora in a research note on Tuesday, April 15th. Wells Fargo & Company lifted their price objective on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Bank of America boosted their price objective on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Finally, Evercore ISI raised their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Cencora has a consensus rating of "Moderate Buy" and a consensus target price of $284.55.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer now directly owns 47,582 shares in the company, valued at $13,766,900.06. This trade represents a 9.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,644 shares of company stock worth $9,472,459 in the last quarter. Corporate insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.